/
SCLX
$7.80+$0.69 (+9.70%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$50.0M
7M shares
52-week range
$4.20 – $34.27
12% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
2.00%
Moderate
Price (6 mo)
Loading chart…
Change$-319.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $21.0M | $23.6M | $31.3M | $38.0M | $46.7M | $56.6M | $30.3M |
| Cost of revenue | $5.8M | $2.1M | $3.6M | $10.8M | $15.7M | $16.7M | $15.2M |
| Gross profit | $15.2M | $21.4M | $27.7M | $27.2M | $31.1M | $39.9M | $15.0M |
| Gross margin | 72.4% | 90.9% | 88.4% | 71.6% | 66.5% | 70.5% | 49.7% |
| R&D | $85.5M | $10.0M | $9.2M | $9.1M | $12.7M | $9.6M | $20.7M |
| Operating income | −$138.7M | −$35.3M | −$35.8M | −$50.6M | −$105.4M | −$83.4M | −$272.3M |
| EBITDA | −$158.0M | −$31.5M | −$72.9M | −$9.3M | −$109.1M | −$66.8M | −$357.9M |
| Net income | −$178.6M | −$47.5M | −$88.4M | −$23.4M | −$114.3M | −$72.8M | −$358.7M |
| Net margin | -849.1% | -201.7% | -282.4% | -61.4% | -244.6% | -128.7% | -1185.8% |
| EPS (diluted) | -1.27 | -0.01 | -23.29 | -6.09 | -44.85 | -19.43 | -36.48 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $66M | $-0.55 | $-0.55–$-0.55 | 1 |
| 2027 | $189M | $0.45 | $0.45–$0.45 | 1 |
| 2028 | $608M | $4.22 | $4.22–$4.22 | 1 |
| 2029 | $944M | $6.79 | $6.79–$6.79 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Scilex Holding Company Common Stock
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
www.scilexholding.com- Employees
- 34
- IPO / List date
- Nov 11, 2022
- HQ
- PALO ALTO, CA
Held by traders on TradeandTell
No one on the platform currently holds SCLX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 36,864 | $245.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-15 | 1-for-35reverse |
| 2010-05-07 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded SCLX yet.
